鼻窦黏膜黑色素瘤免疫治疗的疗效

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.

作者信息

Kshirsagar Rijul S, Eide Jacob G, Harris Jacob, Abiri Arash, Beswick Daniel M, Chang Eugene H, Fung Nicholas, Hong Michelle, Johnson Brian J, Kohanski Michael A, Le Christopher H, Lee Jivianne T, Nabavizadeh Seyed A, Obermeyer Isaac P, Pandrangi Vivek C, Pinheiro-Neto Carlos D, Smith Timothy L, Snyderman Carl H, Suh Jeffrey D, Wang Eric W, Wang Marilene B, Choby Garret, Geltzeiler Mathew, Lazor Jillian, Mitchell Tara C, Kuan Edward C, Palmer James N, Adappa Nithin D

机构信息

Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente Redwood City Medical Center, Redwood City, California.

Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan.

出版信息

Am J Rhinol Allergy. 2025 Mar;39(2):102-108. doi: 10.1177/19458924241308953. Epub 2025 Jan 9.

DOI:10.1177/19458924241308953

PMID:39782303

Abstract

BACKGROUND

Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.

OBJECTIVE

We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.

METHODS

A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.

RESULTS

52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( = 17, 32.7%) or pembrolizumab ( = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.

CONCLUSION

Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.

摘要

背景

尽管采用了多模式治疗，鼻窦黏膜黑色素瘤的生存率仍很低。虽然免疫疗法（IT）对转移性皮肤黑色素瘤的影响已明确，但关于鼻窦黏膜黑色素瘤的数据相对较少。

目的

我们试图确定鼻窦黏膜黑色素瘤患者的免疫治疗结果。

方法

一项回顾性队列研究评估了在鼻窦黏膜黑色素瘤总体治疗策略中接受免疫治疗的患者。记录患者的人口统计学资料、治疗情况和生存结果。

结果

2000年至2022年期间，52例患者接受了鼻窦黏膜黑色素瘤的免疫治疗，平均年龄为69.1±11.9岁。最常见的治疗方法是手术联合放疗和免疫治疗（n=26，50%）。大多数治疗方案由纳武单抗和伊匹单抗联合使用（n=17，32.7%）或派姆单抗（n=14，26.9%）组成。44.2%的患者出现了报告的并发症。1年、2年和5年的总生存率分别为86.9%、74.1%和39.1%。